Loading...
Market
Impact of Ro's partnership with Eli Lilly on customer base by mid-2025?
2
Resolution / Starting Odds
Increase by less than 10% • 25%
Increase by 10% to 20% • 25%
Increase by 20% to 30% • 25%
Increase by more than 30% • 25%
Ro's customer base reports and press releases
Story
Ro Partners with Eli Lilly to Offer Lower-Priced Zepbound Vials with Cash-Pay Option
Dec 11, 2024, 01:42 PM
Telehealth company Ro has partnered with pharmaceutical giant Eli Lilly to expand access to Zepbound, a weight-loss drug containing tirzepatide. The partnership will enable Ro to offer lower-priced, single-dose vials of Zepbound through LillyDirect, Eli Lilly's self-pay pharmacy channel. Ro patients with on-label prescriptions will have access to the drug starting Wednesday, with a cash-pay option available. This collaboration comes amid ongoing shortages of semaglutide-based drugs, such as Ozempic, and questions about the future of compounded GLP-1 treatments. The announcement has impacted the stock performance of Hims & Hers Health, Inc. (HIMS), a company that sells compounded semaglutide, with shares falling 3.8% pre-market.
View original story
Similar markets
Eli Lilly gains significant market share • 25%
Eli Lilly maintains current market share • 25%
Eli Lilly loses market share • 25%
No significant change • 25%
0 new partnerships • 25%
1-2 new partnerships • 25%
3-4 new partnerships • 25%
5 or more new partnerships • 25%
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
Yes • 50%
No • 50%
Increase by more than 10% • 25%
Increase by 5-10% • 25%
Increase by less than 5% • 25%
No significant change or decrease • 25%
Yes • 50%
No • 50%
Below $45 billion • 25%
$45 billion to $45.5 billion • 25%
$45.5 billion to $46 billion • 25%
Above $46 billion • 25%
$45.4 billion to $46.6 billion • 25%
Less than $45.4 billion • 25%
More than $46.6 billion • 25%
Between $46.0 billion and $46.6 billion • 25%
No reduction • 33%
Up to 25% reduction • 33%
More than 25% reduction • 33%
Significantly increase • 25%
Slightly increase • 25%
No change • 25%
Decrease • 25%